Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience
Saved in:
| Main Authors: | Ricardo D. Parrondo, Saurav Das, Hanna Sledge, Leif Bergsagel, Rafael Fonseca, Nelson Leung, Prashant Kapoor, Morie Gertz, Francis Buadi, Angela Dispenzieri, Jamie Elliott, Andre Fernandez, Caitlin Flott, Asher A. Chanan-Khan, Vivek Roy, Sikander Ailawadhi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-05-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-025-01310-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
by: Ricardo D. Parrondo, et al.
Published: (2020-01-01) -
Elotuzumab for Treatment of Multiple Myeloma (Literature Review)
by: OM Votyakova
Published: (2016-10-01) -
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01) -
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
by: Abiola Bolarinwa, et al.
Published: (2025-04-01) -
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma
by: Seunghee Kim-Schulze, et al.
Published: (2024-04-01)